Fenoterol

The drug Fenoterol-native is intended only for inhaled administration.

20 drops = 1 ml.

1 drop = 50 mcg of fenoterol hydrobromide.

Doses should be selected according to the individual needs of the patient; in addition, during treatment the patient must be under the supervision of a physician.

Attacks of bronchial asthma and other conditions accompanied by reversible airway obstruction

Inhalation. 0.5 ml (10 drops = 0.5 mg of fenoterol hydrobromide) is in most cases sufficient for immediate relief of the attack.

If necessary, re-prescription of the drug is injected in 0.5 ml (10 drops = 0.5 mg of fenoterol hydrobromide) up to 4 times / day, but it is possible to reduce the individual dose depending on the effectiveness of the treatment.

In severe cases, if a dose of 1 ml (20 drops) is ineffective, higher doses from 1 to 1.25 ml (20-25 drops = 1-1.25 mg of fenoterol hydrobromide) may be required.

In extremely severe cases, if the dose of up to 2 ml (40 drops) is ineffective, 2 ml (40 drops = 2 mg of fenoterol hydrobromide) are inhaled under the supervision of a doctor.

Prevention of asthma attacks due to physical stress

Inhalation. 0.5 ml (10 drops = 0.5 mg fenoterol hydrobromide) before exercise.

Treatment begins, as a rule, with the lowest recommended dose.

The recommended dose is diluted with 0.9% sodium chloride solution to a final volume of 3-4 ml, sprayed and inhaled until complete consumption of the resulting dilution.

Fenoterol-native should not be diluted with distilled water. The solution is diluted each time before use; the remains of the diluted solution are poured.

Fenoterol-native is recommended to be used with the use of an inhalation device - a nebulizer. In the presence of oxygen breathing apparatus, the solution is best inhaled at a flow rate of 6-8 l / min.

Fenoterol-native can be inhaled simultaneously with cholino-and mucolytic agents. This applies primarily to drugs ipratropium bromide and ambroxol in the form of solutions for inhalation.

There was no negative effect of the drug on the course of pregnancy. However, for pregnant women (especially in the first trimester), the drug is prescribed only in cases where the intended benefit to the mother outweighs the potential risk to the fetus. The possibility of an inhibitory effect of fenoterol on the contractile activity of the uterus should be considered.

Fenoterol passes into breast milk. The safety of the drug during lactation has not been studied. The use of the drug during lactation is possible only in cases where the intended benefit to the mother outweighs the potential risk to the child.

Other sympathomimetic bronchodilators can be used simultaneously with Fenoterol-native only under medical supervision.

In acute, rapidly aggravated dyspnea, the patient should immediately consult a doctor.

With prolonged use of the drug:

- relief of asthma attacks may be preferable to regular use of the drug (symptomatic treatment);

- it is necessary to conduct regular examination of patients in order to identify the need for additional or more intensive anti-inflammatory treatment (for example, inhaled GCS) in order to control airway inflammation and prevent long-term exacerbations of asthma.

In case of increased bronchial obstruction, it is considered unacceptable and it may even be risky to increase the frequency of beta intake.₂agonists contained in drugs such as Fenoterol Native, in excess of the recommended doses. In such a situation, the treatment plan and, especially, the adequacy of anti-inflammatory therapy should be reviewed.

When treating beta₂agonists may develop severe hypokalemia. Particular caution should be exercised in severe bronchial asthma, since This effect can be enhanced by the concomitant use of xanthine derivatives, GCS and diuretics. During hypoxia, the effect of hypokalemia on the heart rhythm may be enhanced. In such situations, it is recommended to regularly monitor the concentration of potassium in the serum.

In rare cases, myocardial ischemia has been observed, associated with beta₂agonists.

The use of fenoterol in patients with hypokalemia who receive cardiac glycosides can cause arrhythmia.

In patients with diabetes mellitus during treatment, it is necessary to regularly monitor plasma glucose.

The drug contains a stabilizer of disodium edetate, which in some patients may cause bronchospasm.

The use of fenoterol can lead to positive results of tests for the abuse of psychoactive drugs for non-medical indications, as well as for doping in athletes.

Influence on ability to drive motor transport and control mechanisms

Studies on the effect of the drug on the ability to drive vehicles and control mechanisms have not been conducted. In the case of side effects when using the drug should refrain from driving vehicles and driving mechanisms.

Symptoms: tachycardia, increased heartbeat, decrease or increase in blood pressure, increased pulse pressure, chest pain, arrhythmias, feeling of hot flushes to the face, tremor, metabolic acidosis, headache, dizziness, anxiety, agitation, hypokalemia.

Treatment: sedatives, tranquilizers, in severe cases, conduct intensive symptomatic therapy. Beta-blockers may be prescribed as specific antidotes (preferably selective beta₁-blockers); It is necessary to take into account the possibility of increasing bronchial obstruction and carefully select the doses of these drugs in patients suffering from bronchial asthma.